Xanthohumol microbiome and signature in adults with Crohn’s disease (the XMaS trial): a protocol for a phase II triple-masked, placebo-controlled clinical trial

被引：0
作者：
Blake O. Langley
Jennifer Joan Ryan
John Phipps
Lita Buttolph
Brenna Bray
Joseph E. Aslan
Thomas O. Metz
Jan F. Stevens
Ryan Bradley
机构：
[1] Helfgott Research Institute,School of Nursing
[2] National University of Natural Medicine (NUNM),School of Medicine
[3] University of Washington,Biological Sciences Division
[4] Oregon Health and Science University,College of Pharmacy and the Linus Pauling Institute
[5] Pacific Northwest National Laboratory,Herbert Wertheim School of Public Health and Human Longevity Science
[6] Oregon State University,undefined
[7] University of California,undefined
[8] San Diego,undefined
来源：
Trials | / 23卷
关键词：
Natural product; Xanthohumol; Crohn’s disease; Inflammatory bowel disease; Microbiome; Inflammation; Safety; Tolerability; Randomized controlled trial;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
相关论文
共 50 条
  • [1] Xanthohumol microbiome and signature in adults with Crohn's disease (the XMaS trial): a protocol for a phase II triple-masked, placebo-controlled clinical trial
    Langley, Blake O.
    Ryan, Jennifer Joan
    Phipps, John
    Buttolph, Lita
    Bray, Brenna
    Aslan, Joseph E.
    Metz, Thomas O.
    Stevens, Jan F.
    Bradley, Ryan
    TRIALS, 2022, 23 (01)
  • [2] Xanthohumol microbiome and signature in healthy adults (the XMaS trial): a phase I triple-masked, placebo-controlled clinical trial (vol 21, 835, 2020)
    Bradley, Ryan
    Langley, Blake O.
    Ryan, Jennifer J.
    Phipps, John
    Hanes, Douglas A.
    Stack, Emily
    Jansson, Janet K.
    Metz, Thomas O.
    Stevens, Jan Frederik
    TRIALS, 2020, 21 (01)
  • [3] Xanthohumol Microbiome and Signature in Healthy Adults (the XMaS Trial): Safety and Tolerability Results of a Phase I Triple-Masked, Placebo-Controlled Clinical Trial
    Langley, Blake O.
    Ryan, Jennifer Joan
    Hanes, Douglas
    Phipps, John
    Stack, Emily
    Metz, Thomas O.
    Stevens, J. Frederik
    Bradley, Ryan
    MOLECULAR NUTRITION & FOOD RESEARCH, 2021, 65 (08)
  • [4] Cedirogant in adults with psoriasis: a phase II, randomized, placebo-controlled clinical trial
    Tyring, Stephen
    Moore, Angela
    Morita, Akimchi
    Hong, H. Chih-ho
    Song, In-Ho
    Eccleston, Jason
    Levy, Gweneth
    Mohamed, Mohamed-Eslam F.
    Qian, Yuli
    Wu, Tianshuang
    Pan, Anqi
    Hew, Kinjal
    Papp, Kim A.
    CLINICAL AND EXPERIMENTAL DERMATOLOGY, 2024, 49 (11) : 1347 - 1355
  • [5] Certolizumab Pegol for Active Crohn's Disease: A Placebo-Controlled, Randomized Trial
    Sandborn, William J.
    Schreiber, Stefan
    Feagan, Brian G.
    Rutgeerts, Paul
    Younes, Ziad H.
    Bloomfield, Ralph
    Coteur, Geoffroy
    Guzman, Juan Pablo
    D'Haens, Geert R.
    CLINICAL GASTROENTEROLOGY AND HEPATOLOGY, 2011, 9 (08) : 670 - U84
  • [6] Effects of vedolizumab in Japanese patients with Crohn's disease: a prospective, multicenter, randomized, placebo-controlled Phase 3 trial with exploratory analyses
    Watanabe, Kenji
    Motoya, Satoshi
    Ogata, Haruhiko
    Kanai, Takanori
    Matsui, Toshiyuki
    Suzuki, Yasuo
    Shikamura, Mitsuhiro
    Sugiura, Kenkichi
    Oda, Kazunori
    Hori, Tetsuharu
    Araki, Takahiro
    Watanabe, Mamoru
    Hibi, Toshifumi
    JOURNAL OF GASTROENTEROLOGY, 2020, 55 (03) : 291 - 306
  • [7] Placebo-controlled clinical trial of mesalazine in the prevention of early endoscopic recurrences after resection for Crohn's disease
    Florent, C
    Cortot, A
    Quandale, P
    Sahmoud, T
    Modigliani, R
    Sarfaty, E
    Valleur, P
    Dupas, JL
    Daurat, M
    Faucheron, JL
    Lerebours, E
    Michot, F
    Belaiche, J
    Jacquet, N
    Soule, JC
    Rothman, N
    Gendre, JP
    Malafosse, M
    EUROPEAN JOURNAL OF GASTROENTEROLOGY & HEPATOLOGY, 1996, 8 (03) : 229 - 233
  • [8] Methotrexate in Crohn's disease: Results of a randomized, double-blind, placebo-controlled trial
    Arora, S
    Katkov, W
    Cooley, J
    Kemp, JA
    Johnston, DE
    Schapiro, RH
    Podolsky, D
    HEPATO-GASTROENTEROLOGY, 1999, 46 (27) : 1724 - 1729
  • [9] Effects of vedolizumab in Japanese patients with Crohn’s disease: a prospective, multicenter, randomized, placebo-controlled Phase 3 trial with exploratory analyses
    Kenji Watanabe
    Satoshi Motoya
    Haruhiko Ogata
    Takanori Kanai
    Toshiyuki Matsui
    Yasuo Suzuki
    Mitsuhiro Shikamura
    Kenkichi Sugiura
    Kazunori Oda
    Tetsuharu Hori
    Takahiro Araki
    Mamoru Watanabe
    Toshifumi Hibi
    Journal of Gastroenterology, 2020, 55 : 291 - 306
  • [10] Adrenomedullin for biologic-resistant Crohn's disease: A randomized, double-blind, placebo-controlled phase 2a clinical trial
    Kita, Toshihiro
    Ashizuka, Shinya
    Takeda, Teruyuki
    Matsumoto, Takayuki
    Ohmiya, Naoki
    Nakase, Hiroshi
    Motoya, Satoshi
    Ohi, Hidehisa
    Mitsuyama, Keiichi
    Hisamatsu, Tadakazu
    Kanmura, Shuji
    Kato, Naoya
    Ishihara, Shunji
    Nakamura, Masanao
    Moriyama, Tomohiko
    Saruta, Masayuki
    Nozaki, Ryoichi
    Yamamoto, Shojiro
    Inatsu, Haruhiko
    Watanabe, Koji
    Kitamura, Kazuo
    JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 2022, 37 (11) : 2051 - 2059
12345